XOMA

XOMA Corp. engages in the discovery and development of therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with various assets that provides right to future potential royalty and milestone payments. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.

EMERYVILLE, Calif., Sept. 22, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA)'s Chief Executive Officer, Jim Neal, will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on Tuesday, September 28, 2021, at 10:20 AM PT.

XOMA to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference

EMERYVILLE, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference held on September 13-15, 2021.  The presentation will be available on demand beginning September 13, 2021, at at 7:00 AM ET and can be accessed at https://bit.ly/2X7bWb0.  The presentation can also be accessed by visiting the investor relations section of the Company's website at www.xoma.com.  A replay of the presentation will be available and archived on the site for 90 days after the event.

XOMA to Present at H.C. Wainwright 23rd Annual Global Investment Conference

EMERYVILLE, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today Heather L. Franklin, President and Chief Executive Officer of Blaze Bioscience, Inc., has joined the Company's Board of Directors. Ms. Franklin has significant experience in corporate development and strategy, including over 10 years of experience founding and leading Blaze and 10 years of business development experience prior to that at ZymoGenetics.

XOMA Announces Heather L. Franklin Joins its Board of Directors

Shares of XOMA (NASDAQ:XOMA) were flat after the company reported Q2 results. Quarterly Results Earnings per share increased 12.12% over the past year to ($0.29), which beat the estimate of ($0.35).

Recap: XOMA Q2 Earnings

Added six assets to its portfolio of potential milestone and royalty assets in 2021

XOMA Reports Second Quarter 2021 Financial Results and Highlights Recent Operational Events

Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Xoma (XOMA) Q2 Earnings Expected to Decline

EMERYVILLE, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today NIS793 in combination with standard of care chemotherapy has been granted Orphan Drug Designation in pancreatic cancer by the U.S. Food and Drug Administration.  NIS793 is a potential first in class novel antibody specific for Transforming Growth Factor Beta (TGFβ).  An Orphan Drug Designation grants special status to a drug that treats a rare disease or condition and provides companies certain benefits to encourage the continued development of medicines that bring novel solutions to patients with these severe diseases1.

U.S. Food and Drug Administration has Granted Orphan Drug Designation to XOMA's Licensed anti-TGFβ Asset NIS793

XOMA Corporation (NASDAQ: XOMA) has acquired the royalty interest position Kuros Biosciences holds in Checkmate Pharmaceuticals Inc's (NASDAQ: CMPI) vidutolimod (CMP-001), for $7.0 million upfront plus $166.5 million as sales milestones.  Checkmate currently is enrolling patients in a study with anti-PD-1 refractory advanced melanoma in combination with Bristol Myers Squibb Co's (NYSE: BMY) Opdivo (nivolumab), a PD-1 blocking antibody.

XOMA Buys Royalty, Milestone Interest In Checkmate's Vidutolimod From Kuros Biosciences

Ad hoc announcement pursuant to Article 53 of the SIX listing rules Ad hoc announcement pursuant to Article 53 of the SIX listing rules

Kuros to receive $7 million up front and potentially $166.5 million in future revenues under a royalty purchase agreement with XOMA related to Kuros's license agreement with Checkmate Pharmaceuticals

EMERYVILLE, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today it has acquired the royalty interest position Kuros Biosciences holds in Checkmate Pharmaceuticals' vidutolimod (CMP-001), an advanced-generation Toll-like receptor 9 agonist packaged in a virus-like particle, for $7.0 million upfront plus sales milestones.  Vidutolimod is designed to trigger the body's innate immune system to attack tumors in combination with other therapies.  The U.S. Food and Drug Administration has granted Fast Track designation to vidutolimod for the treatment of certain types of metastatic or unresectable melanoma and an Orphan Drug designation for Stages IIb - IV melanoma.

XOMA Acquires Royalty and Milestone Interest in Checkmate's Vidutolimod (CMP-001) from Kuros Biosciences

Tesla

Textron

Nutrien

Oasis Petroleum

Stem, Inc

Tata Motors

Two Harbors Investment

Stocks were mostly higher in midday Tuesday trading, after both the S&P 500 and the Nasdaq closed at record highs on Monday.

Stem, Tesla, Textron, Two Harbors and More Tuesday Afternoon Analyst Calls

EMERYVILLE, Calif., May 21, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) recently learned its licensees are presenting at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held June 4-8, 2021, in a virtual setting.

XOMA Licensees to Present Significant Clinical Data at 2021 ASCO Annual Meeting

XOMA's portfolio of potential milestone and royalty assets now has greater than 70 drug candidates. Company ended the first quarter of 2021 with $67.8 million in cash.  The April 2021 $40 million Series B Perpetual Preferred Stock offering paying 8.375% dividend increased XOMA's cash and restricted cash to over $100 million. Board of Directors approved first quarterly dividend payment for XOMAP. On May 3, XOMA announced Janssen had dosed the first patient in a Phase 3 clinical study, resulting in a $0.5 million milestone.

XOMA Reports First Quarter 2021 Financial Results and Highlights Recent Operational Events

EMERYVILLE, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has earned a $0.5 million milestone from Janssen Biotech, Inc. (Janssen), as a result of the first patient dosed in a Phase 3 clinical trial evaluating one of Janssen's biologic assets.

XOMA Earns Milestone for First Patient Dosed in Phase 3 Development Program

Brookfield Renewable Partners

First Guaranty Bancshares

KKR Real Estate Finance Trust

New Residential Investment

OFS Credit Company Inc

Textainer Group Holdings Limited

XAI Octagon Floating Rate & Alternative Income Term Trust

As April 2021 comes to a close, we look back at the new preferred stocks and ETDs introduced during the month, offering annual yields ranging from 4.625 to 8.375 percent. Here is a comparison, against highest quality preferred stocks in our coverage universe, as ranked by our internal “CDx3 Compliance Score” metric.

New Preferred Stock IPOs, April 2021

EMERYVILLE, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) today announced its portfolio of potential future milestone and royalty assets has increased with the addition of three Affimed N.V. (Nasdaq: AFMD) innate cell engager (ICE®) programs for which XOMA could receive future economics. In 2006, Affimed licensed certain XOMA technologies to further its research and discovery efforts.

XOMA's Royalty Portfolio Grows with Addition of Three Royalty Assets

Raised aggregate gross proceeds of $40 million

XOMA Announces Closing of Depositary Shares Offering and Exercise of Underwriters' Option

Depositary shares represent an interest in 8.375% Series B Cumulative Perpetual Preferred Stock Depositary shares represent an interest in 8.375% Series B Cumulative Perpetual Preferred Stock

XOMA Prices $35 Million Offering of Depositary Shares

EMERYVILLE, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has commenced an underwritten registered public offering of depositary shares, each representing 1/1000th fractional interest in a share of the Company's Series B Cumulative Perpetual Preferred Stock, with liquidation preference of $25.00 per depositary share, subject to market and certain other conditions.  The Company expects to grant the underwriters a 30-day option to purchase additional depositary shares in connection with the offering.

XOMA Announces Offering of Depositary Shares and Series B Cumulative Perpetual Preferred Stock

EMERYVILLE, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors approved a dividend of $0.71875 per share to holders of XOMA's Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP).  The cash dividend will be paid on or about April 15, 2021, to XOMAP holders of record at the close of business on April 2, 2021.

XOMA Announces Approval of First Preferred Stock Dividend

Xoma (XOMA) delivered earnings and revenue surprises of 2.33% and 126.07%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Xoma (XOMA) Beats Q4 Earnings and Revenue Estimates

Recognized revenue of $29.4 million  Six assets in the Company's milestone and royalty portfolio advanced to Phase 2 clinical development  Completed $24.6 million Series A Perpetual Preferred Stock offering paying a 8.625% dividend  Ended 2020 with $84.2 million in cash

XOMA Reports Fourth Quarter and Full-Year 2020 Financial Results and Operating Highlights

Xoma (XOMA) to Report Q4 Results: Wall Street Expects Earnings Growth

XOMA has built a large portfolio of drug royalties, over 65, with the potential to build a biotechnology business with high upside but limited and diversified downside protection. This royalty aggregator model has the potential to build a substantial balance sheet for XOMA, which will lower the company's cost-of-capital and enable it to build an even larger portfolio.

XOMA: A Royalty Aggregator To Watch

EMERYVILLE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at two upcoming investor conferences:

News for XOMA Stock (XOMA)